News|Articles|October 4, 2024
Quality by Design (QbD) for Biologics: A CDMO's Perspective
Author(s)Catalent
By integrating QbD into the development process, organizations can achieve robust manufacturing processes, regulatory compliance, and commercial success.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
FDA October 2025 Draft Guidance Sparks Industry Biosimilars Buzz
2
How Biopharma Navigates the 2026 Economic Shift
3
Adenovirus Vectors, Cyclodextrins and the Patient Experience: A Deep Dive
4
EC’s High-Dose Aflibercept Approval Highlights Durable Anti-VEGF Retinal Therapy
5